Orca Bio

Chronic graft​ ​versus ​host disease (#GVHD) remains a potentially serious complication after allogeneic stem cell transplant. Learn more about results from the pivotal Phase 3 Precision-T trial which supported the U.S. FDA approval ​of our ​precision-engineered​​​​​​ cell therapy for allogeneic transplant in people with hematological malignancies: bit.ly/4vGQOU0 #CellTherapy #BloodCancer #PrecisionToLife

Following last week’s FDA approval, we are officially stepping into an exciting new chapter. We want to express our gratitude to the patients, providers, advocates​ and everyone at #TeamOrcaBio who made the approval of our precision-engineered cell therapy for allogeneic transplant in people with hematological malignancies possible.   ​​​   Read more: bit.ly/4vGQOU0 #CellTherapy

We are proud to announce the U.S. FDA approval of our new ​​precision-engineered cell therapy for allogeneic transplant in people with hematologic malignancies. This marks a significant milestone for Orca Bio, ​​and most importantly, for the patients we serve.  ​​​​​​   Learn more: bit.ly/4vGQOU0 #CellTherapy #BloodCancer

Innovation in cell therapy is evolving the way patients living with #bloodcancer are treated. We’re proud to be at the forefront of advancing a pipeline of investigational therapies designed to deliver more precise, differentiated approaches for patients. Learn more about our therapies: bit.ly/4b4E3tT #CellTherapy

Orca Bio announces new East Coast manufacturing capacity and the strategic expansion of its Sacramento-based manufacturing team ahead of potential launch. Read more in our press release: bit.ly/4uGIGl5

As we mark Pride Month, we’re reflecting on what it truly means to foster an environment built on celebrating one another for exactly who we are. At Orca Bio, it's about the daily efforts that ensure every individual feels secure enough to be themselves. Our Chief Financial Officer, Josh Murray, shares his perspective on why this matters to our team. For him, inclusion is a commitment to actively supporting our people, laying the essential groundwork that empowers our people to bring their full potential to the table. We are proud to stand with our LGBTQ+ community this month and every month, continuing the daily work of building a culture where everyone belongs. #Pride2026 #CultureOfBelonging

On #NationalCancerSurvivorsDay, we recognize the strength of every person who has fought cancer and the lifelong journey many survivors continue to navigate. Today, we stand in solidarity with cancer survivors, like Keith, recognizing the courage it takes to move forward and the resilience that continues long after treatment ends. Visit @BloodCancerUtd for resources on survivorship: bit.ly/4eqHTQb #NCSD2026 #CancerResearch #CellTherapy

Orca Bio's Kelly Terrell was on the ground in St. Louis this past weekend to attend @BloodCancerUtd's Visionaries of the Year event. There, she joined other advocates passionate about driving meaningful change for patients and families impacted by blood cancers. Thank you to Blood Cancer United and everyone who joined together in support of this shared mission. Together, we can make a difference!

This #NationalCancerResearchMonth, we’re continuing to celebrate the scientists and researchers working to bring new treatments from the lab to patients. Thank you to Senior Scientist Angela Chen for sharing what continues to inspire her work, and its potential to make a difference for patients. #CellTherapy #Hematology

On #WorldBloodCancerDay, we recognize the patients and families affected by blood cancer and reaffirm our commitment to advancing high-precision cell therapies to redefine what’s possible for patients. Meaningful progress takes all of us, united in support of the people we are here to serve. To learn more or get involved, visit @BloodCancerUtd: bit.ly/4uCIvYA #WBCD #CellTherapy

Today, on #ClinicalTrialAwareness Day, we recognize the patients, caregivers, researchers, doctors and clinical teams who make advancing new therapies possible. Clinical trials are essential to translating scientific discovery into meaningful outcomes for patients. At Orca Bio, we are deeply grateful to those who participate in and support our research, helping to move the field of cell therapy forward. #ClinicalTrialsDay #Innovation #CellTherapy

We are thrilled to welcome Dr. Bijan Nejadnik to Orca Bio as Chief Medical Officer. With decades of experience bridging complex clinical innovation with successful global regulatory outcomes, Dr. Nejadnik joins us at a pivotal moment as we transition toward becoming a commercial-stage company. Read more in our press release: bit.ly/492d1CI

May is #NationalCancerResearchMonth, a time to recognize the researchers, clinicians and scientists working to advance new possibilities for patients with cancer. At Orca, we’re proud to be part of that effort by advancing high-precision cell therapies designed to help transform the future of #bloodcancer treatment. #NCRM26 #CancerResearch #CellTherapy #PatientsFirst

Advances in transplant and cell therapy are expanding our understanding of what constitutes meaningful treatment outcomes. With this in mind, we’re working to advance a high-precision approach to #CellTherapy. Learn more about our approach: bit.ly/4vVhu3N #Hematology #Oncology

Today, Orca Bio announced the U.S. FDA has granted RMAT designation to Orca-Q, marking an important milestone for the program and supporting the continued advancement of a new approach in transplant care. Read more in our press release: bit.ly/490Lhhz

Join our Senior Medical Director, Anna Pavlova, next week at the Clinical Trials in Oncology West Coast Conference for insights into navigating trial complexity, overcoming key barriers and advancing innovation in oncology. Learn more: arena-international.com/event/oncology… #ClinicalTrials #CellTherapy #GeneTherapy

Our team will be in San Diego next week to participate in #FiercePharmaEngage. Andrea Blank, Vice President of Medical Affairs, and Adria Carbo, Head of Business Development, will join this year’s program. Looking forward to joining the conversation on key issues shaping biopharma! fiercepharmaengage.com

Today, we announced that the FDA has extended the review timeline for our Biologics License Application for our investigational treatment for hematologic malignancies. Read the full press release:  bit.ly/3PJ79aD

#ICYMI: Last week, our team was on the ground in Madrid for the 52nd Annual Meeting of the @TheEBMT.​​​ ​​​​​​ It was an energizing week of scientific exchange and meaningful conversations with colleagues from across the global transplant community. We’re grateful for the opportunity to share our work and connect with so many dedicated to advancing care for patients worldwide. #EBMT26 #CellTherapy #Hematology